Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
-0.71%-8.73%-4.56%+9.80% 46.05B
+0.21%-3.37%+403.76%+534.40% 43.59B
+1.74%-3.63%+42.37%+22.59% 42.35B
+1.38%-4.46%+10.38%+79.88% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.87%-2.81% - - 17.16B
+0.75%-0.99%+23.25%+116.71% 16.28B
-0.31%-3.76%+12.33%+30.49% 14.32B
+1.93%-5.14%+81.55%+39.31% 13.03B
Average +0.86%-4.76%+72.42%+108.96% 29.32B
Weighted average by Cap. +0.11%-5.10%+87.28%+129.28%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!